co-occurrence of MYD88 & CD79B mutations, BCL2/MYC double expression, strong enrichment in ABC-DLBCL signatures, NF-κB activation, IRF4 & MYC upregulation;. Here, IRF4 is linked to diffuse large B-cell lymphoma.